acute hepatitis B virus infection
diseaseOn this page
Also known as acute hepatitis B
Summary
acute hepatitis B virus infection (MONDO:0100370) is a disease and 2 clinical trials. Top therapeutic interventions include lactose monohydrate, silibinin, and silybin a. A subtype of hepatitis B virus infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | acute hepatitis B virus infection |
| Mondo ID | MONDO:0100370 |
| ICD-10-CM | B16 |
| ICD-11 | 1337277167 |
| NCIT | C157781 |
| Is cancer (heuristic) | no |
Also known as: acute hepatitis B
Disease family
This is a subtype of hepatitis B virus infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Hepadnaviridae infectious disease › hepatitis B virus infection › acute hepatitis B virus infection
Related subtypes (1): chronic hepatitis B virus infection
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00755950 | PHASE2/PHASE3 | TERMINATED | Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis |
| NCT05264272 | Not specified | UNKNOWN | Disease Loads and Status of Treatment |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LACTOSE MONOHYDRATE | 3 | 1 |
| SILIBININ | 3 | 1 |
| SILYBIN A | 3 | 1 |
| CHEMBL5308485 | 0 | 1 |
| SILYBIN B | 0 | 1 |
| SILYMARIN | 0 | 1 |
Related Atlas pages
- Drugs: Lactose Monohydrate, Silibinin, Silybin A